{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:18:13Z","timestamp":1787912293218,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"crossref","award":["FNR\/P13\/6682797"],"award-info":[{"award-number":["FNR\/P13\/6682797"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s41669-021-00321-3","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T16:02:42Z","timestamp":1642348962000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and Cost of Care for Parkinson\u2019s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-1709","authenticated-orcid":false,"given":"Susanne","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christell","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Konsbruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Perquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejko","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Huiart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,16]]},"reference":[{"issue":"6","key":"321_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM De Lau","year":"2006","unstructured":"De Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol"},{"issue":"1","key":"321_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"E Dorsey","year":"2018","unstructured":"Dorsey E, et al. The emerging evidence of the Parkinson pandemic. J Parkinson\u2019s Dis. 2018;8(1):S3\u20138.","journal-title":"J Parkinson's Dis."},{"issue":"4","key":"321_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"321_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations the movement disorder society task force on rating scales for Parkinson\u2019s disease. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fnagi.2018.00326","volume":"10","author":"G Hipp","year":"2018","unstructured":"Hipp G, et al. The Luxembourg Parkinson\u2019s study: a comprehensive approach for stratification and early diagnosis. Front Aging Neurosci. 2018;10:326.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"321_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mds.25292","volume":"28","author":"SL Kowal","year":"2013","unstructured":"Kowal SL, et al. The current and projected economic burden of Parkinson\u2019s disease in the United States. Mov Disord. 2013;28(3):311\u20138.","journal-title":"Mov Disord"},{"issue":"3","key":"321_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00019053-199814030-00006","volume":"14","author":"RC Dodel","year":"1998","unstructured":"Dodel RC, et al. The economic impact of Parkinson\u2019s disease. Pharmacoeconomics. 1998;14(3):299\u2013312.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"321_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00019053-199916010-00006","volume":"16","author":"C LePen","year":"1999","unstructured":"LePen C, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson\u2019s disease. Pharmacoeconomics. 1999;16(1):59\u201369.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"321_CR9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.20609","volume":"20","author":"DM Huse","year":"2005","unstructured":"Huse DM, et al. Burden of illness in Parkinson\u2019s disease. Movem Disord. 2005;20(11):1449\u201354.","journal-title":"Movem Disord"},{"issue":"8","key":"321_CR10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2165\/00019053-200523080-00007","volume":"23","author":"AE Spottke","year":"2005","unstructured":"Spottke AE, et al. Cost of illness and its predictors for Parkinson\u2019s disease in Germany. Pharmacoeconomics. 2005;23(8):817\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"321_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/mds.20727","volume":"21","author":"K Noyes","year":"2006","unstructured":"Noyes K, et al. Economic burden associated with Parkinson\u2019s disease on elderly Medicare beneficiaries. Mov Disord. 2006;21(3):362\u201372.","journal-title":"Mov Disord"},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.parkreldis.2007.06.003","volume":"13","author":"LJ Findley","year":"2007","unstructured":"Findley LJ. The economic impact of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13:S8\u201312.","journal-title":"Parkinsonism Relat Disord"},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jocn.2020.01.057","volume":"74","author":"M Prado Jr","year":"2020","unstructured":"Prado M Jr, Jamora RD. Cost of Parkinson\u2019s disease among Filipino patients seen at a public tertiary hospital in Metro Manila. J Clin Neurosci. 2020;74:41\u20136.","journal-title":"J Clin Neurosci"},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2147\/CIA.S151919","volume":"12","author":"TM Bovolenta","year":"2017","unstructured":"Bovolenta TM, et al. Average annual cost of Parkinson\u2019s disease in S\u00e3o Paulo, Brazil, with a focus on disease-related motor symptoms. Clin Interv Aging. 2017;12:2095.","journal-title":"Clin Interv Aging"},{"key":"321_CR15","first-page":"3410946","volume":"2017","author":"TM Bovolenta","year":"2017","unstructured":"Bovolenta TM, et al. Systematic review and critical analysis of cost studies associated with Parkinson\u2019s disease. Parkinson\u2019s Dis. 2017;2017:3410946.","journal-title":"Parkinson\u2019s Dis."},{"issue":"10","key":"321_CR16","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/mds.21035","volume":"21","author":"M Ragothaman","year":"2006","unstructured":"Ragothaman M, et al. Direct costs of managing Parkinson\u2019s disease in India: concerns in a developing country. Mov Disord. 2006;21(10):1755\u20138.","journal-title":"Mov Disord"},{"issue":"9","key":"321_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/mds.20999","volume":"21","author":"G Wang","year":"2006","unstructured":"Wang G, et al. Economic burden of Parkinson\u2019s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord. 2006;21(9):1439\u201343.","journal-title":"Mov Disord"},{"issue":"9","key":"321_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40273-013-0075-0","volume":"31","author":"SJ Johnson","year":"2013","unstructured":"Johnson SJ, et al. Costs of Parkinson\u2019s disease in a privately insured population. Pharmacoeconomics. 2013;31(9):799\u2013806.","journal-title":"Pharmacoeconomics"},{"key":"321_CR19","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"3","key":"321_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/aje\/kwr081","volume":"174","author":"F Moisan","year":"2011","unstructured":"Moisan F, et al. Prediction model of Parkinson\u2019s disease based on antiparkinsonian drug claims. Am J Epidemiol. 2011;174(3):354\u201363.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"321_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/ene.12592","volume":"22","author":"P Blin","year":"2015","unstructured":"Blin P, et al. Parkinson\u2019s disease incidence and prevalence assessment in F rance using the national healthcare insurance database. Eur J Neurol. 2015;22(3):464\u201371.","journal-title":"Eur J Neurol"},{"issue":"11","key":"321_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353.","journal-title":"Lancet Neurol"},{"issue":"7243","key":"321_CR23","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","volume":"320","author":"SG Thompson","year":"2000","unstructured":"Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320(7243):1197\u2013200.","journal-title":"BMJ"},{"issue":"13","key":"321_CR24","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, et al. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583\u201390.","journal-title":"Mov Disord"},{"issue":"4","key":"321_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","volume":"15","author":"S von Campenhausen","year":"2005","unstructured":"von Campenhausen S, et al. Prevalence and incidence of Parkinson\u2019s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473\u201390.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"321_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-017-0038-9","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinson\u2019s Dis. 2018;4(1):1\u20137.","journal-title":"NPJ Parkinson's Dis"},{"issue":"2","key":"321_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1600-0404.2011.01517.x","volume":"125","author":"J L\u00f6kk","year":"2012","unstructured":"L\u00f6kk J, et al. Drug and treatment costs in Parkinson\u2019s disease patients in Sweden. Acta Neurol Scand. 2012;125(2):142\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"321_CR28","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00415-011-5969-1","volume":"258","author":"P Jennum","year":"2011","unstructured":"Jennum P, et al. The health-related, social, and economic consequences of parkinsonism: a controlled national study. J Neurol. 2011;258(8):1497\u2013506.","journal-title":"J Neurol"},{"issue":"6","key":"321_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000302644","volume":"7","author":"Y Winter","year":"2010","unstructured":"Winter Y, et al. Costs of Parkinson\u2019s disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis. 2010;7(6):365\u201372.","journal-title":"Neurodegener Dis"},{"issue":"9","key":"321_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1468-1331.2010.02984.x","volume":"17","author":"Y Winter","year":"2010","unstructured":"Winter Y, et al. Longitudinal study of the socioeconomic burden of Parkinson\u2019s disease in Germany. Eur J Neurol. 2010;17(9):1156\u201363.","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"321_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2010.04.011","volume":"294","author":"Y Winter","year":"2010","unstructured":"Winter Y, et al. Trends in resource utilization for Parkinson\u2019s disease in Germany. J Neurol Sci. 2010;294(1\u20132):18\u201322.","journal-title":"J Neurol Sci"},{"issue":"6","key":"321_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/mds.21360","volume":"22","author":"P McCrone","year":"2007","unstructured":"McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson\u2019s disease. Mov Disord. 2007;22(6):804\u201312.","journal-title":"Mov Disord"},{"issue":"12","key":"321_CR33","doi-asserted-by":"publisher","first-page":"e0145310","DOI":"10.1371\/journal.pone.0145310","volume":"10","author":"P Martinez-Mart\u00edn","year":"2015","unstructured":"Martinez-Mart\u00edn P, et al. Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis. PLoS ONE. 2015;10(12):e0145310.","journal-title":"PLoS ONE"},{"key":"321_CR34","unstructured":"Eurostat. Healthcare expenditure statistics - Statistics explained. 2017."},{"key":"321_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0072-9752(07)01242-0","volume":"89","author":"LI Golbe","year":"2008","unstructured":"Golbe LI. The epidemiology of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:457\u20139.","journal-title":"Handb Clin Neurol"},{"issue":"9192","key":"321_CR36","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(99)04137-9","volume":"354","author":"A Schrag","year":"1999","unstructured":"Schrag A, Ben-Shlomo Y, Quinn N. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771\u20135.","journal-title":"Lancet"},{"issue":"18","key":"321_CR37","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"IT Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist IT, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736\u201343.","journal-title":"Neurology"},{"issue":"6","key":"321_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14737167.2020.1681266","volume":"20","author":"SI Prada","year":"2020","unstructured":"Prada SI, et al. Direct cost of Parkinson\u2019s disease in a health system with high judicialization: evidence from Colombia. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):587\u201393.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"321_CR39","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.arr.2019.04.005","volume":"53","author":"T Makovski","year":"2019","unstructured":"Makovski T, et al. Multimorbidity and quality of life: systematic literature review and meta-analysis. Ageing Res Rev. 2019;53:100903.","journal-title":"Ageing Res Rev"},{"key":"321_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/PROM.S160843","volume":"10","author":"A Gumber","year":"2019","unstructured":"Gumber A, Ramaswamy B, Thongchundee O. Effects of Parkinson\u2019s on employment, cost of care, and quality of life of people with condition and family caregivers in the UK: a systematic literature review. Patient Relat Outcome Meas. 2019;10:321.","journal-title":"Patient Relat Outcome Meas."},{"issue":"6","key":"321_CR41","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/mds.27302","volume":"33","author":"S Weir","year":"2018","unstructured":"Weir S, et al. Short-and long-term cost and utilization of health care resources in Parkinson\u2019s disease in the UK. Mov Disord. 2018;33(6):974\u201381.","journal-title":"Mov Disord"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-021-00321-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T12:50:35Z","timestamp":1650977435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-021-00321-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1007\/s41669-021-00321-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received funding from the Fonds National de Recherche (FNR) Luxembourg within the context of the National Centre for Excellence in Research on Parkinson\u2019s disease (NCER-PD) and within the PEARL Excellence Programme (FNR\/P13\/6682797) to RK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Susanne Schmitz received funding from the NCER-PD to conduct the work presented in this article. Christel Renoux is a recipient of a Chercheur-Boursier Salary Award from the Fonds de recherche du Qu\u00e9bec \u2013 Sant\u00e9. Rejko Kr\u00fcger serves as an Editorial Board Member of the European Journal of Clinical Investigation, the Journal of Parkinsonism and Related Disorders, and the Journal of Neural Transmission, and has received research grants from Fonds National de Recherche de Luxembourg (FNR) as Coordinator of the NCER-PD and Coordinator of the Study on COvid-19 National survey for assessing VIral spread by Non-affected CarriErs (CON-VINCE), as well as speaker\u2019s honoraria and\/or travel grants from Abbvie, Zambonm and Medtronic. He also participated as Principal Investigator (PI) or site PI for industry-sponsored clinical trials without receiving honoraria. Robert L. Konsbruck, Pierre Hertz, Magali Perquin, Lukas Pavelka, Michel Vaillant, and Laetitia Huiart have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data the analysis is based on is not publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code to conduct the analysis is specific to the data format provided and is not published with the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SS led the conception, organisation and execution of the research project, designed and executed the statistical analysis and wrote the first draft of the manuscript. MV guided the conception of the project and the design of the statistical analysis, and also reviewed and critiqued the draft document. CR provided guidance on the design and execution of the analysis. RLK provided guidance on the data and was involved in the execution of the data analysis. PH guided the design of the project and reviewed and critiqued the manuscript. MP and LP provided valuable input at the conception stage of the project and reviewed and critiqued the manuscript. RK guided the conception and organisation of the project, and reviewed and critiqued the manuscript. LH guided the conception and organisation of the project and provided guidance on the design and execution of the analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study received ethical approval from the CNER (Comit\u00e9 National d\u2019Ethique de Recherche, Luxembourg).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}